Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM1CKZ)

Drug Name

3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile Drug Info

Synonyms

507268-13-5; CHEMBL365499; 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile; 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]Benzonitrile; 3-(5-(pyridin-2-yl)-2h-tetrazol-2-yl)benzonitrile; 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile; SCHEMBL660355; CTK1G6179; DTXSID70436690; OGIBYDWBTRKAOL-UHFFFAOYSA-N; ZINC3962980; BDBM50151907; AKOS015995227; RP28801; DA-05371; DB-050669; KB-233258; FT-0760671; J-510771; 3-[5-(2-Pyridinyl)-2H-tetrazole-2-yl]benzonitrile; Benzonitrile, 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10198811
CAS Number: CAS 507268-13-5
TTD Drug ID: DMM1CKZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Metabotropic glutamate receptor 5 (mGluR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFQ056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[2]
ADX-48621	DM6GTMD	Parkinson disease	8A00.0	Phase 2/3	[3]
RG-7090	DMX8JYN	Fragile X syndrome	LD55	Phase 2	[4]
STX-107	DMLNKX7	Autism spectrum disorder	6A02	Phase 2	[5]
ADX10059	DMGVKHQ	Anxiety disorder	6B00-6B0Z	Phase 2	[6]
McN3377	DMTCADJ	Fragile X syndrome	LD55	Phase 1/2	[7]
MK-3328	DMW2O5D	Alzheimer disease	8A20	Phase 1	[8]
[3H]fenobam	DMBOXA1	Allodynia	MB40.1	Phase 1	[9]
RG7342	DMIW5NG	Schizophrenia	6A20	Phase 1	[10]
BMS-984923	DMFNDUL	Alzheimer disease	8A20	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Metabotropic glutamate receptor 5 (mGluR5)	TTHS256	GRM5_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter
2	Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
3	Pipeline of Addex Pharma. Addex Pharma. 2009.
4	The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
5	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
6	A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
7	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
9	Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
10	Clinical pipeline report, company report or official report of Roche.
11	Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.